Capital eventCH·1mo ago✦ enriched
Series B financing of USD 30M completed in August 2026 - Novago Therapeutics : Novago Therapeutics
NovaGo Therapeutics completed a USD 30 million Series B in August 2026, led by Neurimmune and Pureos with both existing and new investors, augmented by non-dilutive funding from the Swiss Paraplegic Foundation and Wings for Life for CNS Nogo-A programs.
WARM· 55intent / 100
▸ why this score▾ score breakdown
- default: P(contract_to_capital_90d) · p=0.38 × w=3.0+1.1
- default: OON discount · × 0.75-0.4
- Final score (ambiguity-dampened) · default=55+55
- V2 winner: default · default=55+0